Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study

0566255 - MBÚ 2023 RIV US eng J - Článek v odborném periodiku
Rob, F. - Schierová, Dagmar - Stehlíková, Zuzana - Kreisinger, J. - Roubalová, Radka - Coufal, Štěpán - Mihula, Martin - Jacková, Zuzana - Kverka, Miloslav - Thon, Tomáš - Kostovčíková, Klára - Bajer, Lukáš - Drastich, P. - Trešňák Hercogová, J. - Nováková, M. - Kolář, M. - Vašátko, M. - Lukáš, M. - Tlaskalová-Hogenová, Helena - Jirásková Zákostelská, Zuzana
Association between ustekinumab therapy and changes in specific anti-microbial response, serum biomarkers, and microbiota composition in patients with IBD: A pilot study.
PLoS ONE. Roč. 17, č. 12 (2022), č. článku e0277576. ISSN 1932-6203. E-ISSN 1932-6203
Grant CEP: GA MZd(CZ) NV18-09-00493; GA MZd(CZ) NV18-05-00394
Institucionální podpora: RVO:61388971
Klíčová slova: inflammatory bowel disease * biological therapy * anti-IL-12/IL-23 * microbiome * biomarkers * antibacterial antibody
Obor OECD: Microbiology
Impakt faktor: 3.7, rok: 2022
Způsob publikování: Open access
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0277576

Ustekinumab, is a new therapy for patients with IBD, especially for patients suffering from Crohn’s disease (CD) who did not respond to anti-TNF treatment. To shed light on the longitudinal effect of ustekinumab on the immune system, we investigated the effect on skin and
gut microbiota composition, specific immune response to commensals, and various serum biomarkers.

Trvalý link: https://hdl.handle.net/11104/0337642